Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Anpalakhan, Shobana; Signori, Alessio; Cortellini, Alessio; Verzoni, Elena; Giusti, Raffaele; Aprile, Giuseppe; Ermacora, Paola; Catino, Annamaria; Pipitone, Stefania; Di Napoli, Marilena; Scotti, Vieri; Mazzoni, Francesca; Guglielmini, Pamela F.; Veccia, Antonello; Maruzzo, Marco; Schinzari, Giovanni; Casadei, Chiara; Grossi, Francesco; Rizzo, Mimma; Montesarchio, Vincenzo; Verderame, Francesco; Mencoboni, Manlio; Zustovich, Fable; Fratino, Lucia; Accettura, Caterina; Cinieri, Saverio; Tondini, Carlo Alberto; Camerini, Andrea; Banzi, Maria Chiara; Sorarù, Mariella; Zucali, Paolo Andrea; Vignani, Francesca; Ricciardi, Serena; Russo, Antonio; Cosenza, Agnese; Di Maio, Massimo; De Giorgi, Ugo; Pignata, Sandro; Giannarelli, Diana; Pinto, Carmine; Buti, Sebastiano; Fornarini, Giuseppe; Rebuzzi, Sara Elena; Rescigno, Pasquale; Addeo, Alfredo; Banna, Giuseppe L.; Bersanelli, Melissa

doi:10.1016/j.isci.2023.107970

Cited by 9 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The statistical significance of these findings was maintained even after adjusting for potential confounders in a multivariable model, suggesting the role of dNLR as an independent prognostic factor [62]. A consistently independent effect of the NLR on OS in patients with NSCLC, renal cell cancer, and melanoma was observed in a sub-analysis of the INCIDIa-2 study, which showed a significantly longer OS in patients with low NLR levels (<3.4) [93]. Moreover, as already observed with chemotherapy, a dynamic evaluation of the NLR may help with monitoring the efficacy of ICI.…”

Section: Prognostic Value Under Immunotherapymentioning

confidence: 84%

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Mosca,

Nigro,

Pagani

et al. 2023

Biomolecules

View full text Add to dashboard Cite

In the era of immunotherapy, identifying biomarkers of immune system activation has become a high-priority challenge. The blood neutrophil-to-lymphocyte ratio (NLR) has been largely investigated as a biomarker in several cancer types. NLR values have been shown to mirror the tumor-induced inflammatory status and have been demonstrated to be a reliable prognostic tool across stages of disease and therapeutic approaches. When integrated with other biomarkers of response to immunotherapy, such as PD-L1, tumor mutational burden, and tumor-associated immune cells, the NLR may allow to further stratify patients with different likelihoods of deriving a significant clinical benefit. However, despite its accessibility, low cost, and easy interpretation, the NLR is still poorly used as a prognostic tool in daily clinical practice. In this review, we analyze the role of the NLR in defining the relationship between cancer and the immune system, its usefulness in daily clinical practice, and its relationship with other established or emerging biomarkers of immunotherapy outcomes.

show abstract

Section: Prognostic Value Under Immunotherapymentioning

confidence: 84%

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Mosca,

Nigro,

Pagani

et al. 2023

Biomolecules

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

“…Moreover, the independent effect of the NLR on overall survival in patients with NSCLC as well as other tumors (renal cell carcinoma and melanoma) was observed in a sub-analysis of the INVIDIa-2 study [10]. Anpalakhan et al [10] showed significantly longer OS in patients with low NLR values (< 3.4). They concluded that the NLR could significantly predict OS in the first line as well as in second and subsequent lines of treatment and could be defined as a prognostic factor in NSCLC, renal cell carcinoma, and melanoma patients treated with ICIs [10].…”

Section: Discussionmentioning

confidence: 95%

“…High PLR levels may be associated with immune suppression and impaired lymphocyte function, limiting the ability of the immune system to recognize and eliminate cancer cells, thus reducing the efficacy of immunotherapy. As for the PLR, the elevation of platelet count accelerates tumor progression by promoting the formation of new blood vessels and the production of adhesion molecules [10]. The platelet count is a non-specific indicator of the tumor, and it increases in patients with advanced-stage cancer, so the PLR1 may not differ significantly between groups of patients with favorable and non-favorable immunotherapy outcomes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review

Jankowski,

Krzyżanowska,

Wojas-Krawczyk

et al. 2024

Oncol Clin Pract

View full text Add to dashboard Cite

“…This is consistent whether the patient is being treated in a first-line setting or beyond. [ 62 ] In conclusion, SII can be used as an effective biomarker and easily accessible prognostic marker for patients undergoing ICIs.…”

Section: The Relationship Between Tumors and Inflammationmentioning

confidence: 99%

Advances in systemic immune inflammatory indices in non-small cell lung cancer: A review

Mao,

Cao,

et al. 2024

Medicine

View full text Add to dashboard Cite

Lung cancer is one of the most prevalent cancers globally, with non-small cell lung cancers constituting the majority. These cancers have a high incidence and mortality rate. In recent years, a growing body of research has demonstrated the intricate link between inflammation and cancer, highlighting that inflammation and cancer are inextricably linked and that inflammation plays a pivotal role in cancer development, progression, and prognosis of cancer. The Systemic Immunoinflammatory Index (SII), comprising neutrophil, lymphocyte, and platelet counts, is a more comprehensive indicator of the host’s systemic inflammation and immune status than a single inflammatory index. It is widely used in clinical practice due to its cost-effectiveness, simplicity, noninvasiveness, and ease of acquisition. This paper reviews the impact of SII on the development, progression, and prognosis of non-small cell lung cancer.

show abstract

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Cited by 9 publications

References 43 publications

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond

Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review

Advances in systemic immune inflammatory indices in non-small cell lung cancer: A review

Contact Info

Product

Resources

About